{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:32:57Z","timestamp":1787167977140,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1124\/dmd.122.001132","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T14:40:17Z","timestamp":1669992017000},"page":"276-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Quantitative Cytochrome P450 3A4 Induction Risk Assessment Using Human Hepatocytes Complemented with Pregnane X Receptor-Activating Profiles"],"prefix":"10.1016","volume":"51","author":[{"given":"Aynur","family":"Ekiciler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Li Kelly","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.001132_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.toxlet.2011.02.004","article-title":"Modulation of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) by 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives, ligands of peripheral benzodiazepine receptor (PBR)","volume":"202","author":"Anderson","year":"2011","journal-title":"Toxicol Lett"},{"key":"10.1124\/dmd.122.001132_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/psp4.12619","article-title":"PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction","volume":"10","author":"Bolleddula","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.001132_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007691-199802000-00011","article-title":"Phenytoin auto-induction","volume":"20","author":"Chetty","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.122.001132_bib4","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1124\/dmd.120.000111","article-title":"Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery","volume":"48","author":"Davies","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.001132_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/clpt.2013.170","article-title":"Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data","volume":"95","author":"Einolf","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001132_bib7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1124\/dmd.117.076851","article-title":"Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions","volume":"45","author":"Einolf","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib9","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1124\/dmd.112.047456","article-title":"Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships","volume":"40","author":"Fahmi","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib10","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1128\/AAC.02294-12","article-title":"Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state","volume":"57","author":"Fan-Havard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.001132_bib11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cpt.2503","article-title":"Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective","volume":"112","author":"Hariparsad","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001132_bib12","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.122.001132_bib13","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/jps.23570","article-title":"The utility of modeling and simulation in drug development and regulatory review","volume":"102","author":"Huang","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.122.001132_bib14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1124\/dmd.107.020016","article-title":"Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies","volume":"36","author":"Kanebratt","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib15","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1124\/dmd.118.081927","article-title":"Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance","volume":"46","author":"Kenny","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.121.000765","article-title":"Estimation of Fraction Metabolized by Cytochrome P450 Enzymes Using Long-Term Cocultured Human Hepatocytes","volume":"50","author":"Klammers","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib17","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.122.001132_bib14321593","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1124\/dmd.122.001132_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bdd.2212","article-title":"In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development","volume":"41","author":"Lu","year":"2020","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.122.001132_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cpt.539","article-title":"Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency","volume":"102","author":"Luzon","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001132_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clpt.2004.07.003","article-title":"In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam","volume":"76","author":"Masica","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001132_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1515\/dmpt-2016-0028","article-title":"Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction","volume":"31","author":"Njuguna","year":"2016","journal-title":"Drug Metab Pers Ther"},{"key":"10.1124\/dmd.122.001132_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/psp4.12203","article-title":"Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective","volume":"6","author":"Sato","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.001132_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1124\/dmd.117.078972","article-title":"Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics","volume":"46","author":"Sato","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/dmd.117.075481","article-title":"Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions","volume":"45","author":"Sun","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/JOE-12-0297","article-title":"Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor","volume":"216","author":"Takeshita","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1124\/dmd.122.001132_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001132_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070330","article-title":"Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data","volume":"8","author":"Yamashita","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.122.001132_bib29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/psp4.12458","article-title":"Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction","volume":"8","author":"Yamazaki","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.001132_bib30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.001132_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40495-016-0062-1","article-title":"A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?","volume":"2","author":"Wei","year":"2016","journal-title":"Curr Pharmacol Rep"},{"key":"10.1124\/dmd.122.001132_bib32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1124\/dmd.114.058602","article-title":"Evaluation of calibration curve-based approaches to predict clinical inducers and noninducers of CYP3A4 with plated human hepatocytes","volume":"42","author":"Zhang","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001132_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1087057104264902","article-title":"Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays","volume":"9","author":"Zhu","year":"2004","journal-title":"J Biomol Screen"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.001132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:59:44Z","timestamp":1739937584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624009541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0090955624009541"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.001132","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative Cytochrome P450 3A4 Induction Risk Assessment Using Human Hepatocytes Complemented with Pregnane X Receptor-Activating Profiles","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.001132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}